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Background: The adipose tissue synthetises a whole series of 
hormones which are involved in the regulation of energy homeostasis, 
lipid metabolism and the action of insulin. Among those 
cytokines, adiponectin, one of the most produced adipocyte factors, 
is a recently identified adipocyte-derived protein associated 
with metabolic abnormalities such as obesity, insulin resistance 
and diabetes. The level of adiponectin is reduced in obesity 
and type II diabetes. Metabolic disorders are a growing concern 
in patients treated with antipsychotic medication. In this crosssectional 
study, we wanted to assess the adiponectin levels of 
schizophrenic patients. The first goal was to evaluate whether 
adiponcetin levels fluctuate in the same way as the general nonschizophrenic 
population and also to evaluate whether these would 
be influenced by the presence of metabolic abnormalities and/or 
the antipychotic treatments. 
Methods: Fasting adiponectin levels were assessed in a crosssectional 
sample of 294 patients with schizophrenia treated with 
antipsychotic medication. The mean age of the patients was 
36.4 years. 68% of the patients were male. The majority of 
the patients were treated with only one antipsychotic(85.4%). 
88% of the patients received a second generation antipsychotic. 
The patients are enrolled in a prospective study evaluating the 
metabolic effects of antipsychotics. All underwent an extensive 
metabolic screening, including an oral glucose tolerance test. 
patients were initiated on an overnight fast and were monitored 
during the OGTT. The influence of adiponectin levels on the presence/ 
absence of the metabolic syndrome and the presence/absence 
of glucose abnormalities on continuous variables was assessed 
by means of an independent samples t-test. Patients treated for 
diabetes were excluded form the analysis. The association between 
categorical variables was assesssed by a chi-square test. The study 
was approved by the ethics committee and all the patients gave a 
written informed consent. 
Results: Adiponectin levels are correlated with BMI, and differ 
significantly between patients with normal weight, overweight or 
obesity (p = 0.0001). Patients meeting criteria for the metabolic 
syndrome, either with NCEP ATP-III criteria (28.2%) or with 
the more recent IDF criteria (35.7%), have significantly lower 
adiponectin levels than patients without a metabolic syndrome 
(p = 0.0001). Patients without glucose abnormalities (82.7%) have 
significantly higher adiponectin levels compared to patients with 
glucose abnormalities (IFG and/or IGT, 9.9%) or patients meeting 
ADA criteria for diabetes (7.5%) (p = 0.004). Adiponectin levels 
are lowest in diabetic patients. After controlling for BMI, antipsychotic 
medication significantly influences adiponectin levels 
(p<0.01). Adiponectin levels are significantly lower (p <0.05) in 
patients treated with olanzapine. 
Conclusions: In schizophrenic patients, adiponectin levels vary 
in the same way as described in the normal, overweight and obese 
non schizophrenic population. Also, adiponectin levels in schizophrenic 
patients with and without metabolic syndrome mirror what 
is observed in the general population. Preliminary data suggests 
that the antipsychotic treatment may influence adiponectin regulation, 
a finding that should be verified in longitudinal studies. 
 
